Mar 21, 2018
Genmab A/S to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on March 22, 2018
Jan 31, 2018
CAR-T Cell Therapy For Multiple Myeloma Disease and Pipeline Summary
Dec 12, 2017
Late-Breaking Clinical Trials Signal New Therapeutic Options for Many Patients in the Near Term
Dec 12, 2017
DARZALEX® (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible
Dec 11, 2017
New Data for DARZALEX® (daratumumab) Presented at ASH 2017 Showed Feasibility of Subcutaneous Use and Promise of DARZALEX as a Treatment for Smoldering Multiple Myeloma
Dec 11, 2017
PharmaMar Presents Positive Results of the Pivotal Phase III Trial with Plitidepsin in Multiple Myeloma During the ASH Meeting
Dec 05, 2017
SkylineDx Poster Presentations at ASH Meeting Further Validate Use of MMprofiler(TM) with SKY92 in Multiple Myeloma
Nov 21, 2017
Janssen Submits Application to U.S. FDA to Expand Indication for DARZALEX® (daratumumab) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma who are Transplant Ineligible
Nov 01, 2017
ASH 2017: Janssen to Present 40 Abstracts, Including 8 Oral Presentations, with New Data on DARZALEX® (daratumumab), IMBRUVICA® (ibrutinib) and Other Compounds from Robust Portfolio
Oct 31, 2017
Phase 3 Study Of Subcutanous Daratumumab Initiated Using Halozyme's ENHANZE Technology
Jun 16, 2017
DARZALEX® (daratumumab) Approved by the U.S. FDA in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Who Have Received At Least Two Prior Therapies
Jun 04, 2017
Daratumumab Combination Therapy Improved Clinical Outcomes Regardless of Cytogenetic Risk for Previously-Treated Patients with Multiple Myeloma